Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

Latest Articles

  • You have access
    The case for more aggressive screening and treatment of mild thyroid failure
    Alejandro R. Ayala, MD and Leonard Wartofsky, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4) 313-320;

    What do you do if a patient has mildly elevated TSH but normal T4 and T3 levels?

  • You have access
    Cyclooxygenase-2–selective inhibitors: Translating pharmacology into clinical utility
    Bruce N. Cronstein, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-13-SI-19;
  • You have access
    Randomized Trial of Cyclophosphamide Versus Methotrexate for Induction of Remission in “Non-Renal” Anca-Associated Vasculitis
    K de Groot, N Rasmussen, JW Cohen Tervaert, DRW Jayne and
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-116;
  • You have access
    Induction of Necrotizing and Crescentic Glomeru-Lonephritis (NCGN) and Small-Vessel Vasculitis (SVV) by Adoptive Transfer of Anti-Myeloperoxidase (Anti-MPO) Lymphocytes into Recombinase Activating Gene-2 Deficient (Rag-2 -/-) Mice
    H Xiao, P Heeringa, Z Liu, P Hu, M Zhao, Y Aratani, RJ Falk and JC Jennette
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-13;
  • You have access
    Epidemiology of giant-cell arteritis
    Gene G. Hunder, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-79-SII-82;
  • You have access
    Chlamydia Pneumoniae and Giant-Cell Arteritis: Failure to Detect Chlamydia Pneumoniae in Temporal Artery Biopsies by Polymerase Chain Reaction in 90 Cases and 90 Controls
    MJ Regan, BJ Wood, Y-H Hsieh, ML Theodore, TC Quinn, DB Hellmann, WR Green, CA Gaydos and JH Stone
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-27;
  • Is there an age at which we should stop performing screening Pap smears and mammography?
    You have access
    Is there an age at which we should stop performing screening Pap smears and mammography?
    Patricia Harris, MD, MS and Molly Carnes, MD, MS
    Cleveland Clinic Journal of Medicine April 2002, 69 (4) 272-273;

    Mammography is reasonable if life expectancy is at least 5 years, but screening for cervical cancer is more complex.

  • You have access
    The B-type natriuretic peptide assay: A rapid test for heart failure
    W. Frank Peacock, MD
    Cleveland Clinic Journal of Medicine March 2002, 69 (3) 243-251;

    This 15-minute test is highly sensitive and fairly specific and is useful in evaluating suspected heart failure in outpatients and in emergency care.

  • What is hemochromatosis?
    You have access
    What is hemochromatosis?
    Cleveland Clinic Journal of Medicine March 2002, 69 (3) 238;
  • You have access
    Hereditary hemochromatosis: A common, often unrecognized, genetic disease
    Geraldine M. McCarthy, MD, Conor J. McCarthy, MD, Dermot Kenny, MD, John Crowe, MD, PhD and Stephen Eustace, MB
    Cleveland Clinic Journal of Medicine March 2002, 69 (3) 224-237;

    Although hereditary hemochromatosis is one of the most common genetic diseases affecting people of northern European descent, it is underdiagnosed.

Pages

  • Previous
  • Next
  • 1
  • …
  • 390
  • 391
  • 392
  • 393
  • 394
  • 395
  • 396
  • 397
  • 398
  • …
  • 798

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire